Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.

AIDS Research and Human Retroviruses
Vinie KouamouDavid Katzenstein

Abstract

Barriers to sustainable virologic suppression (VS) of HIV-infected adolescents and young adults include drug resistance mutations (DRMs) and limited treatment options, which may impact the outcome of second-line antiretroviral therapy (ART). We sequenced plasma viral RNA from 74 adolescents and young adults (16-24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. We evaluated first-line nucleoside reverse transcriptase inhibitor (NRTI) susceptibility scores to first- and second-line regimens. Boosted protease inhibitor (bPI)-based ART was provided and viral load (VL) monitored for ≥48 weeks. Fisher's exact test was used to evaluate factors associated with VS on second-line regimens, defined as VL <1,000 copies/mL (VS1,000) or <50 copies/mL (VS50). The 74 participants on first-line ART had a median [interquartile range (IQR)] age of 18 (16-21) years and 42 (57%) were female. The mean (±standard deviation) duration on ART was 5.5 (±3.06) years and the median (IQR) log10 VL was 4.26 (3.78-4.83) copies/mL. After switching to a second-line PI regimen, 88% suppressed to <1,000 copies/mL and 76% to <50 copies/mL at ≥48 weeks. A new NRTI was associated with increased VS50 (p = .031). The...Continue Reading

References

Oct 7, 2004·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Africa HolguínVincent Soriano
Aug 4, 2005·Bioinformatics·Tulio de OliveiraAnne-Mieke Vandamme
Mar 15, 2006·The Journal of Antimicrobial Chemotherapy·Patricia K LeeRichard E Nettles
May 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark OetteDieter Häussinger
May 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tommy F Liu, Robert W Shafer
May 9, 2008·AIDS Research and Human Retroviruses·Jeffrey A AndersonUNKNOWN AIDS Clinical Trials Group Study 359 Protocol Team
Jun 30, 2011·Research in Social & Administrative Pharmacy : RSAP·Arijit GanguliDick R Gourley
Jan 31, 2012·Intervirology·Michele W TangRobert W Shafer
Mar 27, 2012·The Journal of Infectious Diseases·Kim C E SigaloffUNKNOWN PharmAccess African Studies to Evaluate Resistance (PASER)
Jun 14, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Richard A MurphyJean B Nachega
Jan 12, 2013·AIDS Research and Human Retroviruses·Victor MusiimePeter Mugyenyi
Dec 29, 2013·Journal of the International AIDS Society·Antoine JaquetJoseph Drabo
Apr 16, 2014·Antimicrobial Agents and Chemotherapy·Patrick RyscavageBabafemi Taiwo
Apr 22, 2014·Journal of Visualized Experiments : JoVE·Justen ManasaTulio De Oliveira
May 6, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carole L WallisUNKNOWN A5230 team
Feb 7, 2015·BMC Medical Research Methodology·Olayidé BoussariUNKNOWN ANRS 1215 study group
Apr 18, 2015·Open Forum Infectious Diseases·Christina KonstantopoulosJonathan Z Li
Nov 18, 2015·BMC Infectious Diseases·Nicolette Nabukeera-BarungiNathan Tumwesigye
Mar 3, 2017·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Juliana Costa de AbreuCarlos Brites
Sep 28, 2017·Journal of the International AIDS Society·Ragna S BoermaUNKNOWN Paediatric Second-line Study Group
Nov 1, 2017·AIDS Research and Human Retroviruses·Beth ChaplinPhyllis J Kanki
Nov 8, 2017·The Lancet Infectious Diseases·James G HakimUNKNOWN Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team
Nov 8, 2017·The Lancet Infectious Diseases·Andrew M Hill, Francois Venter
Mar 24, 2018·Southern African Journal of HIV Medicine·Graeme MeintjesFrancois Venter

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

Geneious
Stata
REGA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.